Shed vs Willow: Coaching and Compounded Options vs Oral GLP-1
Shed vs Willow quickly: Shed pairs name-brand and compounded GLP-1 options with integrated coaching and a 2-minute approval assessment; Willow focuses on an oral GLP-1 program with progress tracking and follow-up. Early verdict: choose Shed if you want combined medication choice plus continuous coaching; choose Willow if you prefer an oral GLP-1 path with structured tracking and follow-up.
See Shed’s name-brand and compounded options
How Shed and Willow differ at a glance
Both platforms are telehealth-first and require a licensed clinician to confirm medical appropriateness. The most distinctive supported differences are medication form and options, coaching and follow-up, pricing disclosures, assessment speed, and emphasis on progress tracking. Below we compare those points directly using only supplied facts.
1. Medication types and regulatory notes
Shed offers both FDA-approved name-brand GLP-1 medications and compounded GLP-1 options on one platform. The source explicitly states that compounded medications are not FDA-approved and are prepared by a licensed pharmacy based on a provider’s prescription. Willow positions an oral GLP-1 program; the captured evidence notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both providers require a clinician to determine whether treatment is medically appropriate.
2. Coaching, follow-up, and progress tracking
Shed integrates continuous coaching into treatment rather than only issuing a prescription. The platform markets continuous coaching to support titration, lifestyle changes, and plateaus. Willow emphasizes progress tracking tools and follow-up consultations as part of a structured weight management journey. Both present behavioral support, but Shed highlights ongoing coaching bundled into its plans while Willow highlights structured follow-up and tracking infrastructure.
3. Pricing and assessment transparency
Shed advertises specific starting figures for compounded injections and a promotional offer: compounded Semaglutide injections starting at $199 per month and compounded Tirzepatide injections starting at $299 per month, plus a stated 10% off your first month. Shed also notes it does not publish a single standard price online and that patients receive a personalized quote after intake. Willow captured evidence lists a starting price of 299 and indicates higher monthly entry pricing for some plans in the pros and cons, but captured landing-page details were not readable and shipping or fee details were not verified on the captured page.
4. Speed of assessment and workflow
Shed advertises a 2-minute online approval assessment to check eligibility before clinician review. Willow describes a simple digital workflow and telehealth team but the captured evidence does not specify an assessment duration. For users prioritizing a very quick initial eligibility check, the supplied evidence supports Shed’s 2-minute assessment claim.
Comparison table: Shed vs Willow
| Criteria | Shed | Willow |
|---|---|---|
| Medication types | FDA-approved name-brand and compounded GLP-1 options | Oral GLP-1 program; approval status to be confirmed |
| Regulatory note | Compounded meds not FDA-approved; prepared by licensed pharmacy | Branded and compounded products are not interchangeable; status must be confirmed |
| Coaching and follow-up | Continuous coaching integrated into treatment | Progress tracking tools and follow-up consultations |
| Assessment/workflow speed | 2-minute approval assessment before clinician review | Simple digital workflow; assessment duration not supplied |
| Starting price evidence | Compounded Semaglutide starting at $199/month; compounded Tirzepatide starting at $299/month; 10% off first month | Starting price shown as 299; captured page not fully readable |
Explore Willow’s oral GLP-1 program
Clinical claims and evidence notes
Shed references clinical trial averages for Wegovy in its materials and includes a Terms and Conditions note that results may vary. The source repeatedly cautions that compounded medications are not FDA-approved and that treatment is available only when a licensed clinician determines it is medically appropriate. Willow’s captured content emphasizes converting medication efficacy into sustainable outcomes via tracking and follow-up but does not supply trial figures or detailed evidence in the captured page.
Start Shed’s 2-minute assessment
Which to choose: final guidance for Shed vs Willow
Choose Shed if you want both name-brand and compounded GLP-1 options with integrated, continuous coaching and a fast 2-minute eligibility assessment. Shed also advertises specific starting figures for compounded injections and a 10% first month offer for new patients.
Choose Willow if you prefer an oral GLP-1 program framed as a structured weight management journey with progress tracking and follow-up consultations and are focused on a tracking-heavy digital experience.
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →